Research progress on delivery strategies combining DNA nanostructures and plant-derived bioactive compounds for cancer treatment
Year: 2026
Type: article
Abstract: Plant-derived anticancer compounds, including vinblastine (VBL), camptothecin (CPT), and paclitaxel (PTX), have attracted considerable interest in cancer therapy. Although VBL and PTX are established chemotherapeutic agents, the clinical development of CPT itself has been limited by poor aqueous solubility, instability under physiological conditions, and toxicity. DNA nanostructures, polymeric and lipid-based nanocarriers, and aptamer-functionalized delivery systems offer potential strategies to address these limitations. This review summarizes representative strategies for the delivery of VBL, CPT, and PTX, with particular emphasis on the distinct roles of DNA nanostructures as drug carriers, plasmid DNA as a genetic payload, and DNA aptamers such as AS1411 as targeting ligands. Drug incorporation mechanisms, including covalent conjugation, non-covalent loading, and encapsulation, are distinguished from co-delivery strategies involving multiple therapeutic payloads. Representative applications of DNA nanostructures and AS1411-functionalized nanocarriers in preclinical cancer research are reviewed, with attention to their delivery mechanisms and potential limitations. Furthermore, analytical characterization, drug-release behavior, carrier stability, and major challenges in clinical translation are considered. Although these approaches have demonstrated promising results in preclinical studies, further investigation of their pharmacokinetics, safety, reproducibility, and therapeutic efficacy is required to support clinical development.
Source: Biomedical Analysis
Authors: Xin Tong, Lu Ga, Lan Yu, Ailing Su, Jun Ai
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: diamond
OpenAlex ID: W7225995906
